N/A
Completed N=10
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
Plaque psoriasis · Psoriasis Arthropathica · Pustular Psoriasis · erythrodermic psoriasis
Source: ClinicalTrials.gov NCT03885089 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcomePrimary: Number of Participants With Adverse Drug Reactions — 2 Participants
Summary
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under actual status of use.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Drug Reactions |
2 | — |
| SECONDARY Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response |
0.0 | — |
| SECONDARY Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response |
0.0 | — |
| SECONDARY Change From Baseline in Body Surface Area Involvement (BSA) |
0.00; 30.00; 30.00 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis who started treatment with this drug
- Patients who received this drug for the first time at the medical institution after the day of launch of this drug.
Data sourced from ClinicalTrials.gov (NCT03885089). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.